EXELEXELIXIS, INC.同业对比
EXELIXIS, INC. 与iShares Biotechnology ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:IBB 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXEL本股 | $14.1B#10 | 17.9x#2 | 7.6x#4 | 6.1x#4 | 7.0%#7 | 50.1%#8 | 37.6%#2 | 42.4%#3 | 0.0%#9 | — | 45.1%#1 | — |
| VRTX | $130.0B#3 | 29.9x#6 | 6.4x#3 | 10.8x#8 | 8.9%#6 | 838.1%#3 | 34.8%#3 | 19.5%#7 | 25.0%#4 | — | 31.1%#2 | — |
| AMGN | $203.5B#1 | 23.4x#5 | 17.4x#7 | 5.5x#3 | 10.0%#5 | 88.5%#6 | 24.7%#8 | 66.0%#2 | 15.1%#6 | — | — | 2.5%#1 |
| GILD | $183.2B#2 | — | 15.5x#6 | 6.2x#5 | 2.4%#8 | 1672.9%#2 | 34.0%#4 | 71.9%#1 | 26.7%#3 | — | — | 2.2%#2 |
| REGN | — | 19.2x#3 | — | — | 1.0%#10 | 2.1%#9 | 24.9%#7 | 14.2%#8 | 9.4%#8 | — | — | — |
| ARGX | $61.0B#4 | — | — | 1715.5x#10 | 254.4%#1 | 55.1%#7 | 2965.7%#1 | — | — | — | — | — |
| ALNY | $32.0B#6 | 41.7x#7 | 23.7x#8 | 8.6x#7 | 65.2%#3 | 212.8%#4 | 13.5%#10 | 23.2%#5 | 150.5%#1 | — | — | — |
| BIIB | $31.9B#7 | 23.2x#4 | 2.2x#1 | 3.2x#1 | 2.2%#9 | -20.8%#10 | 28.7%#6 | 8.7%#9 | 13.0%#7 | 4#2 | — | — |
| ILMN | $34.6B#5 | 42.7x#8 | 12.2x#5 | 8.0x#6 | -0.7%#11 | 169.5%#5 | 18.6%#9 | 30.0%#4 | 22.0%#5 | 7#1 | — | — |
| INSM | $26.8B#8 | — | 35.3x#9 | 44.2x#9 | 66.7%#2 | -39.7%#11 | -205.6%#11 | -168.6%#10 | -163.0%#10 | 3#3 | -15.3%#3 | — |
| INCY | $24.9B#9 | 17.6x#1 | 4.4x#2 | 4.8x#2 | 21.2%#4 | 3846.9%#1 | 29.5%#5 | 22.9%#6 | 49.0%#2 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议